Given Imaging seeks FDA approval for GI tract capsule

Editorial Staff | | Health Imaging | Oncology Imaging

Given Imaging has filed an FDA application seeking regulatory clearance to market its PillCam Colon 2 capsule for visualization of the lower gastrointestinal (GI) tract.

PillCam Colon 2 is complementary to colonoscopy, and provides an alternative method of lower GI tract imaging for patients who are unable to undergo colonoscopy, according to the Yoqneam, Israel-based company.

Given submitted the FDA application through a direct de novo pathway, which the company said should expedite the approval process under new guidelines.

Editorial Staff

Related Content

MRI-first approach could allow many to safely forego prostate biopsy
MRI guidance significantly reduces radiotherapy side effects compared to CT
Interventional procedure often as effective as surgery for difficult-to-treat liver cancer
AI tumor volume estimations could improve prostate cancer treatment strategies
MRI could be 'powerful tool' for guiding surgery decisions in patients with rectal cancer
Breast cancer only visible via MRI is often less aggressive

Around the web

Cardiovascular Business
Cardiology, radiology specialists debate CCTA’s rise as a go-to imaging modality for CAD

CCTA is being utilized more and more for the diagnosis and management of suspected coronary artery disease. An international group of specialists shared their perspective on this ongoing trend.

Cardiovascular Business
New AI program delivers rapid, accurate echo video assessments

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Radiology Business
Key Medicare reimbursement and No Surprises Act updates from RSNA 2024

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.